Quick Answer
Candel Therapeutics, Inc. reported Diluted EPS of $0.72 per share (loss) for fiscal year 2025.
Candel Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.72 | +58.6% |
| 2024 | -$1.74 | -32.8% |
| 2023 | -$1.31 | -101.5% |
| 2022 | -$0.65 | +66.0% |
| 2021 | -$1.91 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.21 | +36.4% | -133.3% |
| June 30, 2025 | -$0.09 | +87.8% | -169.2% |
| March 31, 2025 | $0.13 | +146.4% | +139.4% |
| September 30, 2024 | -$0.33 | -13.8% | +55.4% |
| June 30, 2024 | -$0.74 | -124.2% | -164.3% |
| March 31, 2024 | -$0.28 | +6.7% | +3.4% |
| September 30, 2023 | -$0.29 | +3.3% | +12.1% |
| June 30, 2023 | -$0.33 | -135.7% | -10.0% |
- Candel Therapeutics, Inc. showed an increase of +58.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Candel Therapeutics, Inc.’s diluted eps has grown by 62.3% (from $1.91 per share (loss) to $0.72 per share (loss)).
- The most recent figure is from Candel Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: